Quotient Investors’s Edwards Lifesciences EW Stock Holding History

Quotient Investors’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-7,800	Closed	-$205K	–	222
2015 Q4	$205K	Sell	7,800 -1,662	-18%	-$43.2K	0.08%	203
2015 Q3	$224K	Sell	9,462 -16,938	-64%	-$409K	0.05%	184
2015 Q2	$627K	Buy	26,400 +7,200	+38%	+$162K	0.09%	157
2015 Q1	$456K	Buy	+19,200	New	+$431K	0.06%	173

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Quotient Investors's EW Position: Q1 2016 in Review

Quotient Investors sold out of Edwards Lifesciences (EW) in Q1 2016, closing a stake of 7,800 shares — an estimated $205K sold.

Quotient Investors first reported a position in EW in Q1 2015 and held it in 4 quarters. The position peaked at $627K in Q2 2015. 659 funds tracked by Wall St. Rank hold EW as of Q1 2016.

Quotient Investors reported no remaining Edwards Lifesciences position as of Q1 2016 after selling out during the quarter.
Quotient Investors sold 7,800 Edwards Lifesciences shares in Q1 2016, an estimated $205K.
Quotient Investors first reported a position in Edwards Lifesciences in Q1 2015 and held it in 4 quarters.
Quotient Investors's Edwards Lifesciences position peaked at $627K in Q2 2015.
659 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2016.

Based on Quotient Investors's 13F filing for Q1 2016, filed 14 Apr 2016.